Abbott Laboratories's Stock Analysis

Abbott Laboratories Announces $20 Billion Senior Notes Offering

Abbott Laboratories has entered into a pricing agreement to issue $20 billion in senior notes, which includes various floating and fixed-rate notes with maturities ranging from 2029 to 2066. The offering is set to close on March 9, 2026, and the notes will be sold under a prospectus supplement filed with the SEC.

The net proceeds from this offering will be used primarily to finance the acquisition of Exact Sciences Corporation, pay off Exact Sciences' existing debts, cover related fees and expenses, and for general corporate purposes. Abbott has included customary representations, warranties, and covenants in the pricing agreement, and it will also indemnify the underwriters against certain liabilities related to the offering.

Feb 26, 2026 16:16:53

Abbott Laboratories Board Size Reduced to Twelve Members

Abbott Laboratories' Board of Directors has amended its By-Laws to reduce the number of board members from thirteen to twelve. This change will take effect on April 24, 2026. The amendment was made on February 20, 2026, as part of a restructuring of the board's composition.

Feb 20, 2026 16:17:51

Abbott Laboratories Reports Q4 and Full-Year 2025 Results

Abbott Laboratories announced its financial results for the fourth quarter and full year of 2025, reporting a fourth-quarter GAAP diluted EPS of $1.01 and an adjusted diluted EPS of $1.50, reflecting a 12% growth. For the full year, the company reported GAAP diluted EPS of $3.72 and adjusted diluted EPS of $5.15, marking a 10% growth. Fourth-quarter sales increased by 4.4% on a reported basis, with full-year sales reaching $44.3 billion, an increase of 5.7%. Abbott's management highlighted the exclusion of COVID-19 testing sales from organic growth metrics to better reflect core business performance.

Looking ahead, Abbott projects full-year 2026 organic sales growth between 6.5% and 7.5%, with adjusted diluted EPS anticipated to be between $5.55 and $5.80. The company also announced an agreement to acquire Exact Sciences to strengthen its position in the cancer diagnostics market, expected to close in the second quarter of 2026. Additionally, Abbott declared a quarterly dividend of $0.63 per share, marking the 408th consecutive dividend payment, and underscoring its commitment to returning value to shareholders.

Jan 22, 2026 07:35:32

Abbott Laboratories Expands Board of Directors to Thirteen Members

Abbott Laboratories has appointed Nita Ahuja, M.D. to its Board of Directors, increasing the board size from twelve to thirteen members, effective December 12, 2025. This change reflects the company’s ongoing commitment to enhancing its governance and oversight capabilities.

The company’s by-laws were also amended to outline the processes for shareholder nominations and proposals during annual meetings. Shareholders must adhere to specific notice requirements to propose business or nominate directors, ensuring that the board maintains control over the nomination process and that all shareholder actions are properly documented.

Dec 12, 2025 16:10:48

Abbott Laboratories Announces Blackout Period for Retirement Plans

Abbott Laboratories has announced a Blackout Period affecting its Stock Retirement Plans due to administrative changes, including new recordkeepers and trustees. This period will begin on December 24, 2025, and is expected to end during the week of January 11, 2026. During this time, participants will be unable to make any transactions involving their Plan accounts, including changing contribution rates or diversifying investments in Abbott common shares.

Additionally, directors and executive officers will face trading restrictions on Abbott securities during the Blackout Period, as mandated by the Sarbanes-Oxley Act and Regulation BTR. These restrictions will apply from December 15, 2025, until after the fourth quarter earnings release, and will remain in effect even if the general insider trading policy is lifted. Interested parties can obtain more information about the Blackout Period by contacting Abbott Laboratories directly.

Nov 21, 2025 16:06:09

Abbott to Acquire Exact Sciences for $21 Billion in Cash

Abbott Laboratories has entered into a definitive agreement to acquire Exact Sciences Corporation for $105 per common share, totaling approximately $21 billion. This acquisition aims to enhance Abbott's presence in the cancer diagnostics segment, with Exact Sciences being a leader in early cancer detection and precision oncology. The deal is expected to close in the second quarter of 2026, pending shareholder and regulatory approvals. Following the merger, Exact Sciences will operate as a wholly owned subsidiary of Abbott, contributing to Abbott's diagnostics sales, which will exceed $12 billion annually.

The acquisition is supported by a commitment letter from Morgan Stanley for up to $20 billion in senior unsecured bridge loans. Exact Sciences is projected to generate over $3 billion in revenue this year, with a high teens organic sales growth rate. The merger has been unanimously approved by the boards of both companies, and Abbott plans to hold an investor conference call to discuss the transaction further. Key products from Exact Sciences include Cologuard, Oncotype DX, and Cancerguard, which are significant in the cancer diagnostics market.

Nov 20, 2025 07:37:40

Abbott Laboratories Reports Third Quarter 2025 Financial Results

Abbott Laboratories announced its financial results for the third quarter of 2025, reporting a 6.9% increase in sales on a reported basis and a 5.5% increase on an organic basis. The company achieved a GAAP diluted earnings per share (EPS) of $0.94 and an adjusted diluted EPS of $1.30, which excludes specified items. Year-to-date sales also increased by 6.1% on a reported basis. Abbott reaffirmed its full-year organic sales growth guidance and narrowed the adjusted diluted EPS range to $5.12 to $5.18, indicating expected double-digit growth at the midpoint.

In terms of business segments, worldwide Medical Devices sales increased by 14.8%, with significant growth in Diabetes Care and other areas. Nutrition sales rose by 4.2%, driven by strong growth in Adult Nutrition products. However, Diagnostics sales saw a decrease of 6.6% on a reported basis, largely due to a decline in COVID-19 testing-related sales. Abbott's board declared a quarterly dividend of $0.59 per share, marking the company's 407th consecutive quarterly dividend.

Oct 15, 2025 07:33:48

Abbott Laboratories Reports Second Quarter 2025 Financial Results

Abbott Laboratories reported a 7.4% increase in sales for the second quarter of 2025, amounting to $11.142 billion. The company achieved a GAAP diluted earnings per share (EPS) of $1.01 and an adjusted diluted EPS of $1.26, reflecting double-digit growth compared to the previous year. Notably, the gross margin improved to 52.7%, with an adjusted gross margin of 57.0%, marking a 100 basis point increase. The growth in sales was driven by strong performance in its Medical Devices and Established Pharmaceuticals segments, while Diagnostics sales experienced a decline due to reduced COVID-19 testing-related revenue.

For the first half of 2025, Abbott reported a 5.7% increase in sales, with projections for the full year indicating organic sales growth of 7.5% to 8.0%, excluding COVID-19 testing-related sales. The company also announced plans to develop a new cardiovascular device manufacturing facility in Georgia, expected to be completed by 2028. Abbott declared its 406th consecutive quarterly dividend of $0.59 per share, payable on August 15, 2025, to shareholders of record by July 15, 2025.

Jul 17, 2025 07:34:53

Abbott Reports 4% Sales Growth and 8% EPS Increase

Abbott reported a first-quarter GAAP diluted earnings per share (EPS) of $0.76 and an adjusted diluted EPS of $1.09, reflecting a growth of 11.2% compared to the previous year. The company experienced a 4.0% increase in reported sales and a 6.9% organic sales growth, which rose to 8.3% when excluding COVID-19 testing-related sales. The gross margin also improved, with an adjusted gross margin of 57.1%, showing a 140 basis point increase. Abbott reaffirmed its full-year financial guidance and highlighted recent advancements in its medical technology, including the CE Mark for its Volt™ PFA System and the initiation of a pivotal trial for its Coronary Intravascular Lithotripsy System in the U.S.

Conversely, Abbott's Diagnostics segment faced challenges with a reported sales decline of 7.2% and an organic decrease of 4.9%, largely due to reduced COVID-19 testing-related sales. The company noted that COVID-19 testing sales dropped to $84 million from $204 million in the prior year. Additionally, established pharmaceuticals sales grew only 2.7% on a reported basis, indicating slower performance in that area. The international markets also showed mixed results, with some segments experiencing declines attributed to foreign exchange impacts and volume-based procurement programs in China.

Apr 16, 2025 07:36:02

Abbott Reports $42 Billion in Full-Year 2024 Sales

Abbott's fourth-quarter sales reached $11.0 billion, marking a 7.2% increase from the previous year, with organic sales growth at 10.1% when excluding COVID-19 testing. The company also reported a full-year 2024 sales total of $42.0 billion, up 4.6% from 2023, and achieved the upper end of its guidance for organic sales growth and adjusted earnings per share. The gross margin improved, and Abbott announced over 15 new growth opportunities from its R&D pipeline throughout the year.

However, Abbott faced challenges in its Diagnostics segment, with sales affected by declines in COVID-19 testing-related revenue, which dropped to $176 million in the fourth quarter from $288 million the previous year. Additionally, the company discontinued the ZonePerfect product line in its Nutrition business, impacting sales figures. Despite these setbacks, Abbott projects continued organic sales growth for 2025 in the range of 7.5% to 8.5%.

Jan 22, 2025 07:13:21